Are you Dr. Bradner?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 128 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
Dana-Farber Cancer Institute
Boston, MA 02115Phone+1 617-632-6629Fax+1 617-632-5168
Summary
- Dr. James Bradner, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Dana-Farber Cancer Institute, Brigham and Women's Faulkner Hospital, and South Shore Hospital.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2005- Brigham and Women's HospitalResidency, Internal Medicine, 1999 - 2002
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1999
Certifications & Licensure
MA State Medical License 2002 - 2025
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2011
Publications & Presentations
PubMed
- 527 citationsThe dTAG system for immediate and target-specific protein degradationBehnam Nabet, Justin M. Roberts, Dennis L. Buckley, Joshiawa Paulk, Shiva Dastjerdi
Nature Chemical Biology. 2018-03-26 - 76 citationsMerkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesisJingwei Cheng, Donglim Esther Park, Christian Berrios, Elizabeth A. White, Reety Arora
Plos Pathogens. 2017-10-13 - 188 citationsDegradation of the BAF Complex Factor BRD9 by Heterobifunctional LigandsDavid Remillard, Dennis L. Buckley, Joshiawa Paulk, Gerard L. Brien, Matthew Sonnett
Angewandte Chemie. 2017-05-15
Press Mentions
Genetic Study Provides First-Ever Insight into Biological Origin of SchizophreniaJune 25th, 2020- Real-Time Transferrin-Based PET Detects MYC-Positive Prostate CancerJune 7th, 2020
SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in CancerJune 6th, 2019- Join now to see all
Grant Support
- Selective Inhibition Of HDAC6 In Cancer TherapyNational Cancer Institute2008–2011
